Table 5.
Selected Prior Studies Evaluating Pre-Operative Treatment of Patients with Borderline Resectable and Locally Advanced PDAC
| Total patients treated | Pre-operative treatment type | Duration of pre-operative treatment | No. of patients surgically explored (% of total patients) | No. of patients undergoing resection (%of total patients) | No. of R0 resections (% of total patients) | Median overall survival of patients after resection, months | |
|---|---|---|---|---|---|---|---|
| Stokes et al (2011)24 | 40 BR | Capecitabine + XRT | 12–41 weeks (median 19) | 21 (52.5%) | 16 (40.0%) | 14 (35.0%) | 23 |
| Katz et al (2012)15 | 122 BR | GEM* + XRT +/− 5-FU or Capecitabine | 2–4 months | 92 (75.4%) | 85 (69.7%) | 81 (66.4%) | 33 |
| Takahashi et al (2013)25 | 80 BR | GEM* + XRT | 3 months | 52 (65.0%) | 32 (40.0%) | --- | a |
| Cho et al (2013)26 | 30 BR | GEM* + XRT | --- | N/A | 30 (N/A) | 29 (N/A) | 45 |
| Rose et al (2014)27 | 64 BR | GEM + Docetaxel +/− other agents +/− XRT | 24 weeks | 39 (60.9%) | 31 (48.4%) | 27 (42.2%) | --- |
| Takeda et al (2014)28 | 35 BR | GEM + XRT | 1–2 months | 27 (77.1%) | 26 (74.3%) | 26 (74.3%) | 41.2 |
| Mellon et al (2015)29 | 110 BR | GTX + XRT | 2–3 months | 56 (50.9%) | 46 (41.8%) | 44 (40.0%) | 19.2 |
| Aristu et al (2003)30 | 47 LA | Cisplatin + 5- FU; Paclitaxel, 5-FU, Cisplatin GEM + Docetaxel; + XRT | Variable | 12 (25.5%) | 9 (19.1%) | --- | 23 |
| Sa Cunha et al (2005)31 | 61 LA | 5-FU + Cisplatin + XRT | Variable | 23 (37.7%) | 13 (21.3%) | 11 (18.0%) | 28 |
| Allendorf et al (2008)32 | 78 LA | GTX + XRT | 3 months | 78 (N/A) | 59 (N/A) | --- | 17.8 |
| Bickenbach et al (2011)33 | 36 LA | GEM* +/− XRT | Variable | N/A | 36 (N/A) | 30 (N/A) | 30 |
| Strobel et al (2012)34 | 257 LA | GEM* +/− XRT | Variable | 137 (53.3%) | 120 (46.7%) | 42 (16.3%) | 12.7 |
| Ben-Josef et al (2012)35 | 50 LA | GEM + XRT | 2–4 months | --- | 12 (24.0%) | 10 (20.0%) | 32 |
| Habermehl et al (2012)36 | 215 LA | GEM + XRT | Variable | 104 (48.4%) | 51 (49.0%) | 20 (39.2%) | 14.4 |
| Mellon et al (2015)29 | 49 LA | FOLFIRINOX + XRT | 2–3 months | 7 (14.3%) | 5 (10.2%) | 5 (10.2%) | 15 |
PDAC indicates pancreatic ductal adenocarcinoma; BR, borderline resectable; LA, locally advanced, XRT, radiation therapy; GEM*, gemcitabine-based multi-agent therapy; GEM, single-agent gemcitabine; 5-FU, 5-fluorouracil; GTX, gemcitabine, docetaxel and capecitabine; FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan and oxaliplatin
--- information not available
a
34% 5 year survival